|Other Names||Serine protease HTRA3, 3421-, High-temperature requirement factor A3, Pregnancy-related serine protease, HTRA3, PRSP|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP13989c was selected from the Center region of HTRA3. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Serine protease that cleaves beta-casein/CSN2 as well as several extracellular matrix (ECM) proteoglycans such as decorin/DCN, biglycan/BGN and fibronectin/FN1. Inhibits signaling mediated by TGF-beta family proteins possibly indirectly by degradation of these ECM proteoglycans (By similarity). May act as a tumor suppressor. Negatively regulates, in vitro, trophoblast invasion during placental development and may be involved in the development of the placenta in vivo. May also have a role in ovarian development, granulosa cell differentiation and luteinization (PubMed:21321049, PubMed:22229724).|
|Cellular Location||Secreted. Note=Secretion increased during decidualization of endometrial stromal cells|
|Tissue Location||Widely expressed, with highest levels in both adult and fetal heart, ovary, uterus placenta, and bladder. In the endometrium, expressed in epithelial glands and the stroma. Also present in leukocytes. Isoform 1 is predominant in heart and skeletal muscle, whereas isoform 2 is predominant in placenta and kidney.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
HTRA3 is probable serine protease.
Zurawa-Janicka, D., et al. Expert Opin. Ther. Targets 14(7):665-679(2010)Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) :Beleford, D., et al. J. Biol. Chem. 285(16):12011-12027(2010)Theoleyre, S., et al. Biochem. Biophys. Res. Commun. 394(3):453-458(2010)Beleford, D., et al. Clin. Cancer Res. 16(2):398-409(2010)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.